Loading...
Printed on 7/19/2026
For informational purposes only. This is not medical advice.
NLR (Neutrophil-to-Lymphocyte Ratio) is a simple hematologic index derived from the CBC differential that serves as a systemic inflammatory and immune stress marker. Normal adult NLR is 1–3; values above 4 suggest significant inflammation; values above 7–10 are associated with adverse outcomes in cancer, sepsis, and cardiovascular disease. NLR reflects the balance between pro-inflammatory innate immunity (neutrophils) and adaptive anti-tumor immunity (lymphocytes). It is extensively validated as an independent prognostic marker in colorectal, lung, gastric, and bladder cancers, and as a severity marker in sepsis and COVID-19. Always interpret in clinical context — corticosteroids, physical stress, and hematologic malignancy confound NLR. Use alongside the complementary [Platelet-to-Lymphocyte Ratio (PLR)](/tools/plr-ratio) for comprehensive inflammatory profiling.
Formula: NLR = Absolute Neutrophil Count / Absolute Lymphocyte Count.
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
NLR is derived entirely from a standard complete blood count (CBC) with differential — no additional tests are required. The CBC differential provides the absolute neutrophil count (ANC, also sometimes listed as 'absolute granulocyte count' or 'segmented neutrophils + bands') and the absolute lymphocyte count (ALC). These are reported directly in units of cells × 10³/µL (equivalent to cells × 10⁹/L internationally). Ensure you are using the ABSOLUTE counts, not the percentage differential. The percentage differential (e.g., 'neutrophils 75%') is only meaningful when combined with the total white cell count. For example, a WBC of 4.0 × 10³/µL with 75% neutrophils = ANC of 3.0 × 10³/µL. Most modern CBC reports provide absolute counts directly. If only percentages are reported, calculate: ANC = WBC × (% neutrophils / 100); ALC = WBC × (% lymphocytes / 100). Document whether the patient has any factors that might confound the CBC differential: recent corticosteroid use (drives neutrophilia and lymphopenia — falsely elevated NLR), physical exercise before the blood draw (transient leukocytosis and shift toward neutrophilia), time of day (diurnal variation — NLR peaks in the morning), recent infection or vaccination (neutrophilia), or hematologic malignancy (alters the differential unpredictably).
NLR = ANC ÷ ALC. This is a simple division performed on the two absolute counts. Example: ANC = 7.2 × 10³/µL, ALC = 1.4 × 10³/µL → NLR = 7.2 ÷ 1.4 = 5.14. Interpret the result using the following general reference ranges (noting that specific cutoffs vary by disease context): **NLR <2:** Optimal. Low inflammatory burden, healthy immune balance. Common in young healthy adults, athletes, and patients with no active inflammatory conditions. NLR <1 may suggest relative lymphocytosis (viral infection, lymphocytic leukemia, adrenal insufficiency). **NLR 2–4:** Normal range for most adult populations. Some studies use 1–3 as the normal range in strictly healthy populations; 2–4 accounts for mild physiologic variation and age effects. **NLR 4–7:** Elevated. Suggests significant systemic inflammatory stress. Common in active bacterial infections, post-operative states, moderate chronic inflammatory diseases (rheumatoid arthritis flare, IBD). Associated with adverse outcomes in multiple conditions. NLR >5 in a patient with fever and clinical signs of infection supports serious bacterial infection in many clinical contexts. **NLR >7–10:** High. Associated with adverse outcomes in cancer, severe sepsis, major trauma, and COVID-19. NLR >10 in cancer patients is associated with significantly reduced overall survival across multiple tumor types. NLR >20 in COVID-19 is associated with ICU admission and mechanical ventilation requirement.
NLR is a context-dependent biomarker — the clinical significance of a specific NLR value depends on the disease being assessed, the patient population, and whether the value represents a baseline or a change from prior measurements. **In oncology:** Pre-treatment NLR predicts outcomes across many solid tumors. High NLR (>3–5, depending on tumor type) reflects systemic inflammatory burden and impaired anti-tumor lymphocyte immunity. It is an independent predictor of reduced overall survival, disease-free survival, and response to chemotherapy in colorectal, lung, gastric, hepatocellular, bladder, and renal cancers. Before immunotherapy (immune checkpoint inhibitors — ICI): baseline NLR >5 predicts poor response to ICI (pembrolizumab, nivolumab, atezolizumab) across multiple tumor types, likely because high NLR reflects lymphocyte exhaustion and an immunosuppressive tumor microenvironment. **In sepsis:** NLR >5 is associated with bacteremia, organ dysfunction, and 30-day mortality. A rising NLR during ICU stay suggests ongoing infection or inadequate source control. **In COVID-19:** NLR >6 at admission predicts severe disease; NLR >20 is a marker for critical illness and cytokine storm. **In cardiovascular disease:** NLR >3 is associated with higher MACE (major adverse cardiovascular events) risk and worse outcomes in acute MI, stable coronary artery disease, and heart failure. Serial NLR measurements over time are more informative than a single value — a rising NLR despite treatment indicates clinical deterioration, while a falling NLR suggests improving inflammatory control.
Oncologists and oncology nurses
Pre-treatment NLR is one of the most extensively validated prognostic biomarkers across solid tumors, derived from a simple CBC. High NLR (>3–5, tumor-type specific) at cancer diagnosis or before initiating systemic therapy independently predicts reduced overall survival, higher recurrence rates, and poorer response to chemotherapy. In patients receiving immune checkpoint inhibitors (ICI), baseline NLR >5 predicts poor response — high NLR reflects lymphocyte dysfunction and an immunosuppressive tumor microenvironment that limits ICI efficacy. Serial NLR during treatment can track inflammatory response: NLR normalization during chemotherapy or immunotherapy suggests treatment response, while persistently high or rising NLR indicates treatment failure or disease progression.
Intensivists and critical care nurses
NLR is a readily available, no-cost biomarker for sepsis severity assessment at ICU admission. NLR >5 in a febrile patient with suspected infection correlates with bacteremia and organ dysfunction. NLR >10 is associated with severe sepsis and higher 30-day mortality. In the ICU, serial NLR tracking complements traditional markers (WBC, CRP, procalcitonin) — a rising NLR despite antibiotics suggests inadequate source control or antibiotic-resistant organisms, while a falling NLR indicates improving infection control. NLR can be calculated at any time a CBC is drawn, making it useful for continuous monitoring without additional test costs.
Emergency medicine physicians and hospitalists
During the COVID-19 pandemic, NLR emerged as one of the strongest predictors of disease severity available from routine admission labs. NLR >6 at hospital admission is associated with ICU requirement, mechanical ventilation, and in-hospital mortality. NLR >20 is a marker for cytokine storm syndrome. Multiple large studies validated NLR as a rapid, low-cost triage tool to identify COVID-19 patients at highest risk of clinical deterioration, enabling appropriate resource allocation (ICU bed assignment, early dexamethasone and tocilizumab administration). The same principles apply to other viral pneumonias with cytokine storm potential (severe influenza, RSV in immunocompromised patients).
Surgeons and perioperative care teams
Pre-operative NLR predicts post-operative complications across surgical specialties. In colorectal cancer surgery, NLR >5 predicts anastomotic leak, wound infection, and 30-day mortality. In cardiac surgery, elevated pre-operative NLR is associated with post-operative atrial fibrillation and prolonged ICU stay. Post-operatively, a rapidly rising NLR on day 1–3 suggests systemic inflammatory response syndrome (SIRS) or early surgical site infection. NLR can be integrated into pre-operative risk calculators (alongside ASA classification and RCRI) to identify patients who may benefit from prehabilitation, nutritional optimization, or enhanced recovery protocols.
Rheumatologists and rheumatology nurses
In autoimmune and inflammatory diseases (rheumatoid arthritis, SLE, inflammatory bowel disease, psoriasis), NLR correlates with disease activity and systemic inflammatory burden. Rising NLR during a rheumatologic flare reflects neutrophil-mediated tissue injury and immune dysregulation. NLR decreases with effective biologic therapy (TNF inhibitors, IL-6 inhibitors) and can serve as an objective, low-cost biomarker of treatment response between formal disease activity assessments. Note: corticosteroids used to treat flares will independently elevate NLR by suppressing lymphocyte counts and mobilizing neutrophils — interpret NLR cautiously during active steroid therapy.
Glucocorticoids (prednisone, dexamethasone, methylprednisolone, hydrocortisone) profoundly alter the CBC differential within hours of administration: they cause neutrophilia (by demarginating neutrophils from blood vessel walls and increasing release from bone marrow) and lymphopenia (by redistributing lymphocytes from blood to lymphoid tissues and inducing lymphocyte apoptosis). A single dose of dexamethasone 10 mg can raise NLR from 3 to 8–12 within 6–8 hours. Any NLR interpretation must note current steroid use. In cancer patients on steroid pre-medication for chemotherapy, NLR measurement should ideally be performed before steroids are given. In COVID-19 patients on dexamethasone, the NLR reflects both disease severity and drug effect — interpret with caution.
NLR is most useful in patients with solid tumors and normal bone marrow function. In hematologic malignancies (leukemia, lymphoma, myeloma), the CBC differential is driven by clonal cell populations rather than physiologic inflammatory responses — NLR in these patients reflects disease biology rather than systemic inflammation and is not interpretable as an inflammatory marker. Similarly, during post-chemotherapy nadir periods, severe neutropenia (ANC <0.5k) makes NLR calculation meaningless (a patient with ANC 0.2 and ALC 0.5 has NLR 0.4, which means nothing about their inflammatory state). Avoid NLR use in: active leukemia, immediately post-chemotherapy, after bone marrow transplantation, or in patients with significant cytopenias from any cause.
The NLR cutoff that predicts adverse outcomes varies by tumor type and has been studied most extensively in: colorectal cancer (NLR >3–5), non-small cell lung cancer (NLR >3–5), gastric cancer (NLR >3), hepatocellular carcinoma (NLR >5), bladder cancer (NLR >2.5–5), renal cell carcinoma (NLR >3), and ovarian cancer (NLR >2.5). These cutoffs are derived from receiver-operating characteristic (ROC) analyses in specific patient cohorts and should not be universally applied. A 'high' NLR in a colon cancer patient (cutoff 5) does not necessarily mean the same prognosis as 'high' in a gastric cancer patient. Review disease-specific literature for the most validated cutoff in your context.
Immune checkpoint inhibitors (ICI — pembrolizumab, nivolumab, atezolizumab, ipilimumab) work by unleashing anti-tumor T-lymphocyte responses. High pre-treatment NLR (>5 in most studies) reflects a systemic inflammatory environment with relative lymphopenia, suggesting impaired T-cell anti-tumor immunity. Multiple retrospective and prospective studies across melanoma, NSCLC, urothelial carcinoma, and other ICI-treated cancers show that high baseline NLR independently predicts shorter progression-free and overall survival. Mechanistically, high NLR reflects neutrophil-mediated immunosuppression in the tumor microenvironment (neutrophils suppress T-cell activity) and functional lymphocyte exhaustion. Some oncologists use NLR as part of the pre-ICI biomarker panel (alongside PD-L1 expression and tumor mutational burden) to counsel patients about expected ICI benefit.
Like cortisol (which drives the diurnal pattern), NLR demonstrates circadian variation: it peaks in the morning (~8–10 AM) when neutrophil counts are highest and lymphocyte counts lowest, and reaches a nadir in the evening (~8–10 PM) when lymphocytes peak. This variation can shift NLR by 20–30% within the same individual on the same day without any change in clinical status. For serial monitoring (tracking disease progression or treatment response), draw blood at consistent times — ideally in the morning before meals and before any procedures or medications. For research applications, specify blood draw timing. This variation is rarely clinically meaningful for a single clinical decision, but it is relevant when comparing values across different time points.
Aging is associated with immunosenescence — a progressive decline in lymphocyte function and count (particularly naive T cells), with relative persistence of innate immune cells including neutrophils. As a result, healthy elderly adults (age >70) have higher baseline NLR than younger adults. A NLR of 4 in a healthy 75-year-old may have no clinical significance, while the same value in a healthy 35-year-old would be mildly elevated. When interpreting NLR in elderly patients, consider age-adjusted reference ranges. Additionally, comorbidities common in elderly patients (heart failure, chronic kidney disease, diabetes, COPD) independently elevate NLR through chronic low-grade inflammation, further raising the baseline.
Serial NLR tracking during cancer treatment (chemotherapy, immunotherapy, radiation) provides real-time information about treatment response. A pattern of falling NLR after initiating treatment suggests the tumor and its inflammatory microenvironment are responding — lymphocyte recovery and reduced neutrophil burden. A stable or rising NLR despite treatment suggests treatment resistance, disease progression, or cumulative immunosuppression from the treatment itself (many chemotherapy agents cause transient lymphopenia). In patients on immunotherapy who develop immune-related adverse events (irAEs — colitis, pneumonitis, endocrinopathies), NLR may rise due to the autoimmune inflammatory response. Integrate serial NLR with imaging response assessments, tumor markers, and clinical evaluation.
NLR and PLR (platelet-to-lymphocyte ratio) are complementary inflammatory indices derived from the same CBC. NLR reflects the innate immune (neutrophil) vs adaptive immune (lymphocyte) balance. PLR reflects the interaction between platelet-driven inflammation/thrombosis and lymphocyte-mediated anti-tumor immunity. When both NLR and PLR are elevated, this indicates multidimensional systemic inflammatory burden — both the neutrophil-driven pro-inflammatory axis AND the platelet-driven pro-inflammatory/pro-thrombotic axis are activated. In cancer prognostication, combined elevation of NLR AND PLR has stronger adverse prognostic significance than either alone. Calculate both from the same CBC for comprehensive inflammatory assessment.
NLR as a prognostic biomarker is extensively reviewed in Templeton et al. (J Natl Cancer Inst 2014) across 100 cancer studies. NLR >5 for sepsis severity reference: Liu et al. (J Inflamm Res 2019). NLR >6 as COVID-19 severity predictor: Yang et al. (JAMA Network Open 2020). NLR should be interpreted in clinical context; no universal cutoff is validated across all diseases. Meta-analyses support its role as an independent prognostic marker in colorectal, lung, and bladder cancers.
NLR <2: optimal, low inflammatory burden. NLR 2–4: normal adult range. NLR 4–7: elevated, suggests significant systemic inflammation or stress. NLR >7–10: high, associated with adverse outcomes in cancer, sepsis, and COVID-19. Always interpret in clinical context — corticosteroids, hematologic malignancy, and physical stress confound interpretation.
Use NLR as an adjunct marker when CBC differential data are available and inflammatory burden, sepsis severity, or cancer prognosis is being assessed. Useful for serial monitoring of treatment response when a baseline is available. Always interpret alongside clinical findings, other laboratory values, and disease-specific context.
NLR is non-specific and affected by corticosteroids (major confounder), infection, physical stress, malignancy, age, and chronic inflammatory disease. Not validated in hematologic malignancies or post-chemotherapy nadir states. No universal cutoff applies across all diseases. Diurnal variation (peaks in morning) affects interpretation. Should not be used as a standalone diagnostic decision tool.
For related assessments, see PLR Ratio, 4T Score (HIT) and DIC Score.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Calculate PLR from platelet and absolute lymphocyte counts as an adjunct inflammatory marker.
OpenHematologyScore HIT pretest probability with the validated 4T tool. Score ≤3: >99% NPV — HIT unlikely. Score ≥4: stop heparin and switch anticoagulants. Free clinical calculator.
OpenHematologyEstimate overt disseminated intravascular coagulation probability using the ISTH scoring framework.
OpenEmergencyCalculate the SOFA score to assess organ dysfunction severity in critically ill patients. Scores range from 0 to 24 across six organ systems.
OpenEmergencyCalculate qSOFA bedside sepsis risk score. A score of 2 or more (altered mentation, RR ≥22, SBP ≤100) flags high-risk infection requiring urgent evaluation.
Open